End-of-day quote
Shenzhen S.E.
06:00:00 2024-07-11 pm EDT
|
5-day change
|
1st Jan Change
|
9.2
CNY
|
+0.44%
|
|
-3.46%
|
-36.99%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,262
|
4,776
|
12,093
|
14,085
|
10,391
|
9,632
|
Enterprise Value (EV)
1 |
3,917
|
4,569
|
11,976
|
14,075
|
10,372
|
9,495
|
P/E ratio
|
-44.5
x
|
75.3
x
|
-61.7
x
|
52
x
|
-706
x
|
-29
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.41
x
|
8.41
x
|
43.7
x
|
35
x
|
29.1
x
|
22.4
x
|
EV / Revenue
|
5.89
x
|
8.05
x
|
43.3
x
|
34.9
x
|
29
x
|
22.1
x
|
EV / EBITDA
|
74.3
x
|
-86
x
|
-59.7
x
|
-97.5
x
|
-93.8
x
|
-109
x
|
EV / FCF
|
-6.47
x
|
11.4
x
|
-1,856
x
|
7,692
x
|
121
x
|
-88.3
x
|
FCF Yield
|
-15.5%
|
8.8%
|
-0.05%
|
0.01%
|
0.83%
|
-1.13%
|
Price to Book
|
1.54
x
|
2.07
x
|
5.71
x
|
5.9
x
|
4.38
x
|
4.66
x
|
Nbr of stocks (in thousands)
|
659,736
|
659,736
|
659,736
|
659,736
|
659,736
|
659,736
|
Reference price
2 |
6.460
|
7.240
|
18.33
|
21.35
|
15.75
|
14.60
|
Announcement Date
|
4/24/19
|
6/23/20
|
4/28/21
|
4/29/22
|
4/26/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
664.6
|
567.6
|
276.8
|
402.7
|
357.1
|
429.8
|
EBITDA
1 |
52.69
|
-53.16
|
-200.7
|
-144.4
|
-110.6
|
-87.43
|
EBIT
1 |
-6.555
|
-111.2
|
-260.3
|
-203.9
|
-175.6
|
-155.8
|
Operating Margin
|
-0.99%
|
-19.58%
|
-94.04%
|
-50.64%
|
-49.17%
|
-36.25%
|
Earnings before Tax (EBT)
1 |
-83.18
|
76.77
|
-201.8
|
278.6
|
12.72
|
-313.2
|
Net income
1 |
-95.79
|
63.38
|
-195.9
|
271
|
-14.69
|
-332.5
|
Net margin
|
-14.41%
|
11.17%
|
-70.78%
|
67.29%
|
-4.11%
|
-77.35%
|
EPS
2 |
-0.1452
|
0.0961
|
-0.2970
|
0.4108
|
-0.0223
|
-0.5039
|
Free Cash Flow
1 |
-605.5
|
402.1
|
-6.454
|
1.83
|
85.69
|
-107.5
|
FCF margin
|
-91.11%
|
70.84%
|
-2.33%
|
0.45%
|
24%
|
-25.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
634.39%
|
-
|
0.68%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/24/19
|
6/23/20
|
4/28/21
|
4/29/22
|
4/26/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
345
|
207
|
117
|
10.6
|
18.5
|
137
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-606
|
402
|
-6.45
|
1.83
|
85.7
|
-108
|
ROE (net income / shareholders' equity)
|
-3.22%
|
2.8%
|
-8.66%
|
12%
|
-0.04%
|
-13.8%
|
ROA (Net income/ Total Assets)
|
-0.1%
|
-1.8%
|
-5.55%
|
-4.9%
|
-3.91%
|
-3.74%
|
Assets
1 |
97,051
|
-3,522
|
3,528
|
-5,529
|
375.8
|
8,889
|
Book Value Per Share
2 |
4.190
|
3.500
|
3.210
|
3.620
|
3.600
|
3.140
|
Cash Flow per Share
2 |
2.340
|
1.700
|
0.4300
|
0.2800
|
0.2800
|
0.2300
|
Capex
1 |
608
|
36.3
|
67.7
|
60.8
|
31.5
|
4.32
|
Capex / Sales
|
91.52%
|
6.39%
|
24.45%
|
15.11%
|
8.81%
|
1%
|
Announcement Date
|
4/24/19
|
6/23/20
|
4/28/21
|
4/29/22
|
4/26/23
|
4/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -36.99% | 837M | | +6.96% | 101B | | +8.29% | 42.63B | | -11.09% | 33.5B | | +82.32% | 29.77B | | -11.82% | 16.14B | | +1.39% | 14.31B | | -12.13% | 11.55B | | +176.65% | 10.53B | | +6.74% | 9.2B |
Biopharmaceuticals
|